New EU Filings
Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
You may also be interested in...
The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.
The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.
Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.